π° Background CRISPR-Cas9 and other gene editing technologies have revolutionized molecular biology, offering unprecedented precision in altering DNA. These tools hold the potential to correct genetic mutations responsible for devastating inherited conditions such as cystic fibrosis, Huntington's disease, and sickle cell anemia. Early research and trials are showing promising results in animal models and some initial human applications. π Context The ability to edit the human genome raises profound ethical, social, and scientific questions. While the prospect of eradicating debilitating diseases is alluring, concerns linger about off-target mutations, unforeseen long-term health consequences, and the potential for non-therapeutic enhancements. The equitable access to such advanced therapies and the very definition of 'disease' versus 'trait' are central to this complex debate. β Pro Proponents argue that gene editing represents a moral imperative to alleviate human suffering and prevent the transmission of inherited diseases. By correcting faulty genes at their source, we can offer permanent cures, dramatically improving quality of life and reducing healthcare burdens. Denying access to such life-saving technology, they contend, would be ethically indefensible when the potential for good is so immense. β Con Opponents express deep concerns regarding the safety and ethical implications of germline gene editing. The risk of introducing unintended genetic changes that could be passed down through generations, potentially leading to new health problems, is a significant worry. Furthermore, there are fears that this technology could exacerbate social inequalities, creating a genetic divide between those who can afford enhancements and those who cannot, and blurring the lines of what it means to be human.